Real-world enfortumab vedotin +/- pembrolizumab (EV+/-P)–based treatment toxicity, treatment discontinuation, and associations with survival in advanced urothelial carcinoma (aUC). Fibroblast growth ...
Long-term safety was stable without emergent signals; grade ≥3 TRAEs stayed ~57–59%, while cumulative neuropathy increased with duration, managed via interruptions and EV dose reductions. Notably, ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, ...
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab Cohort 3 included 41 ...
Stage 1 bladder cancer involves lamina propria invasion without detrusor involvement, requiring both eradication of index lesions and mitigation of field-change–driven multifocal recurrence risk.
An interdisciplinary research team has published new findings that indicate which patients with advanced urothelial carcinoma could benefit in particular from the new targeted therapy with the ...
A simple urine test can accurately diagnose urothelial carcinoma as well as predict the risk for recurrence for those under surveillance, according to findings from a recent validation study. The ...
Source: Getty Images First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results